Objective To investigate the role of losartan in AT2-R mediated renal protective effects in renovascular hypertension rat. Methods Male SD rats were divided into sham group and renovascular hypertension group in which Goldblatt methods were performed. The two groups were intragastically administered with losartan (respectively 0, 10, 20, 30 mg?kg-1?d-1) for 6 weeks. Then renal function was measured, the AT2-R expression in the non-ischemic kidney and the AngⅡ contents in non-ischemic kidney and plasma were determined. Results In renovascular hypertension rats, especially in the contralateral, non-ischemic kidney, the expression of AT2-R protein were up-regulated. Losartan increased the AngⅡ contents in non-ischemic kidney and plasma, mediated the natriuretic/diuretic effect and renal protective effect in renovascular hypertension rat and increased the expression of renal AT2-R. Conclusion In renovascular hypertension rat, losartan mediates renal natriuretic/diuretic effect and protects renal function through up-regulating AT2-R in kidney.

Objective To observe the effects of sympathectomy on the function and the expression level of angiotensin Ⅱ type 1 receptor(AT_(1)R).Methods Newborn male Wistar rats' sympathetic nerve was destroyed by 6-hydroxydopamine(6-OHDA),and then following parameters were observed after 11 weeks: pressor and vasoconstrictive effects of AngⅡ,the affinity of -AngⅡ to AT_(1)R in myocardium,the level of mRNA expression of AT_(1)R in vessel smooth muscle.Results The pressor and vasoconstrictive effects induced by AngⅡand the mRNA expression of AT_(1)R in vessel smooth muscle enhanced substantially in adult rats who had been performed sympathectomy at juvenile period.There was also an enhancement in B_(max) of AT_(1)R in myocardium of the rats performed with sympathectomy,while no change occurred in K_(D).Conclusion In rats performed with sympathectomy,the expression level of AT_(1)R rises remarkably.The pressor and vasoconstrictive effects induced by AngⅡenhance consequently. These might be the reasons that blood pressure and heart rate do not reduce after sympathectomy.

The changes of the spinal cord blood flow(SCBF),the content of TXB2 and 6-keto-PGF1a of the injured segment of the cord and other neurological manifestations were observed on a rat model of spinal cord injury(SCI)established with Allen's weight drop(50g-cm)method and the effects of indomethacin on these changes were studied.It was found that SCBF was significantly reduced in the first 2 hours after SCI and further reduced in the 4th ~ 8th hour.Increase of TXB2 was observed in the 1st hour and reached the peak in the 4th hour.The level of 6-keto-PGF1a was also increased in the 1st hour and maintained at that level for 24 hours.The changes of TXB2/6-keto-PGF1a was similar to those of TXB2.There was a negative correlation of SCHF with TXB2 content and TXB2/6-keto-PGF1a ratio.The intravenous injection of 10mg/kg indomethacin could inhibit the increase of TXB2 content and increase 6-keto-PGF1a content relatively.It could also alleviate or retard the decrease of SCBF after SCI and improve the motar function of the hind limbs of the rats.These findings suggest that indomethacin can improve SCBF and promote the recovery of neurological functions through its regulatory effects on the levels of TXB2 and 6-keto-PGF1a

OBJECTIVE:To establish a HPLC method for determining the concentration of dexketoprofen in rabbit’s pla_ sma.METHODS:Dexketoprofen was extracted from samples with ether.HPLC was performed on C 18 column with methyl al?cohol-50mmol/L sodium dihydrogen phosphate as mobile phase.Detection wavelength was260nm.RESULTS:The linear range was0.05～25?g/ml.Recovery was99.92%～100.54%.Within-day and between-day RSDs were0.56%～2.94%and0.6%～2.89%respectively.CONCLUSION:This method is simple,accurate and good in repetitiveness.Satisfactory results have been obtained in determining plasma concentrations of dexketoprofen in6rabbits after taking dexketoprofen-?-cy?clodextrin inclusion microspheres.

OBJECTIVE:To prepare domiphen bromide osmotic tablets,and to observe,analyze the mechanism of drug release.METHODS:Coating prescription was optimized by uniform design and the cumulative rates of drug release of different formulated preparations were measured,pharmaceutical features of domiphen bromide osmotic tablet and mechanism of drug release were studied.RESULTS:The dosage of PEG-400 and the coating membrane thickness all had an effect on drug release.The optimal coating technique was analyzed as 12%of PEG-400 and 10mg of coating.Spray speed,temperature and rotation speed did not affect releasing profiles.CONCLUSION:Improvement in formulation of coat of domiphen bromide osmotic tablet can result in drug release for 12h,whose mechanism includes diffusion and osmotic pump principle.

Objective To prepare Domiphen osmotic tablets of zero release above 80% in vitro. Methods Coating prescription was optimized by uniform design and the drug release characteristic was tested in vitro. Results The lemma thickness was (shown as lemma weight) 10.75 mg and the content of the porosity-making agent was 12%. The three batchs of drug tablets release pattern were in accord with zero order kinetics during 12 h. Conclusion This method is easy to produce and reaches initial devise request.

As a gray and dynamic system,the life science frontier always exists in a dynamic status or alteration with research hotspots.By analyzing and defining the life science frontier,the author brought forward seven representatives of lire science frontier.which at present include genomics and system biology et al.In the meantime,the characteristics of seven frontiers and its significance for the scientific research management were analyzed with the scientific systemic theory.

The relationship between the inhibitory effect of tetrandrine ( Tet ) on neutrophil ( Nen ) lysomal enzyme ( ?-glu-curonidasc , P-G ) release & calcium ion were studied. It was found that calcium ion added to the medium increased p-G release from Neu During incubation. After intracellular calcium was depleted by EGTA, P-G release was signifcantly decreased. While calcium was added, increase in P-G release reappeared. It indicated that both intracellular & extracellular calcium may be involved in P-G release. Tet & v erapamil ( Ver ) not only inhibited ?-G release induced either by calcium or serum opsonized zymOsan, but also inhibited potential operated channel of Neu. It was concludted that the inhibitory effect of Tet on Neu lysomal enzyme release was concerned with its calcium antagonism.

Objective To prepare microspheres of dextro ketoprofen ? cyclodextrin (S KP ? CD) for prolonging the drug releasing time in vitro . Methods Microspheres containing S KP ? CD were prepared by complex coacervation method with gelatin and acacia. Trap efficiency, drug loading, and drug content were determined. The dissolubility of S KP in the intestinal liquid was compared with that in the gastric liquid. Results In comparison with S KP, microspheres of S KP ? CD possessed slow releasing property. Conclusion Drug microspheres prepared by this simple, easy, and accurate method are of slow releasing property.

Objective To analyze clinical results of newborn hearing concurrent genetic screening and to ex-plore the significance of genetic test and potential correlations between the genotype and clinical phenotype.Methods Newborns in Foshan born during May,2012 and September,2013 were recruited.Two-step hearing screening was carried out by using AABR (automated auditory brainstem response).Blood samples were collected with a standard protocol for testing hot-spot mutations of common deafness-susceptibility genes.ResuIts A total of 10 238 newborns,including 9 295 rooming-in infants and 943 NICU infants,received hearing screening and 99.16%of passed the initial screening.The passing rates of rooming-in and NICU infants were significantly different (χ2 =99.1,P<0.001),but the difference was not significant in the secondary screening (χ2 =0.26,P=0.61).Three hundred and fifteen out of 10 238 (3.08%)newborns who underwent genetic testing were found to have one or two allele mutations of deafness-susceptibility genes,and the positive rate of genetic screening was significantly higher than the referring rate of initial hearing screening (χ2 =123.9,P<0.001).Newborns with gene mutations had high-er referring rate of hearing screening than the general population (χ2 =72.4,P<0.001).GJB2 c.235delC heterozygous mutation frequency was 1.61% (165/10 238),while the homozygous mutation frequency was 0.04% (4/10 238);c.299 300delAT heterozygous mutation frequency was 0.20% (20/10 238);c.176 191del16 heterozygous mutation frequency was 0.06% (6/10 238);no c.35delG mutation was detected.SLC26A4 c.919-2A>G heterozygous mu-tation frequency was 0.80% (82/10 238)and the homozygous mutation frequency was 0.03% (3/10 238);c.2168A>G heterozygous mutation frequency was 0.12% (12/10 238).MTRNR1 1555A>G heteroplasmic mutation fre-quency was 0.04% (4/10 238)while the homoplasmic mutation frequency was 0.18% (18/10 238).1494C>T ho-moplasmic mutation frequency was 0.01% (1/10 238).GJB2 c.235delC and SLC26A4 c.919 -2A>G mutations were found to be the most recurrent mutations in participants,and finally eight infants aged 6 days to 25 months di-agnosed with moderate to very severe sensorineural hearing loss were correlated with these two mutations.ConcIu-sion Genetic screening is a potent strategy to complement the conventional hearing screening since it is helpful for determining high risk individuals and early discovering possible late-onset hearing loss.